The UK’s Redx Pharma has entered into a collaboration with France’s Pierre Fabre Laboratories to develop therapies to tackle skin cancer.
The deal will see the partners work together on the evaluation and development of a small molecule programme for an undisclosed oncology target. Following the first stage of the collaboration, Pierre Fabre will have the option to enter into exclusive negotiations to license global rights for the programme in selected cancer indications.
Financial terms have not been disclosed but Redx chief executive Neil Murray described the deal as “a highly significant milestone”. It represents the first major transaction for the company’s anti-cancer subsidiary and “demonstrates the potential of our oncology pipeline”.
Christian Bailly, head of research at Pierre Fabre Pharmaceuticals, described Redx as “a dynamic and visionary biotech company”, adding that the deal “marks an additional milestone in our partnering research strategy”.
Skin cancers represent 30% of total cancers and the incidence increases by 5% each year.
